{"id":390289,"date":"2019-12-31T00:00:00","date_gmt":"2019-12-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2019-biopharma-breast-cancer-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-28T11:24:20","modified_gmt":"2026-04-28T11:24:20","slug":"dlsfon0001-2019-biopharma-breast-cancer-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2019-biopharma-breast-cancer-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Breast Cancer | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>Characterized by high incidence and <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854604136670195236675\">long<\/gwmw> treatment durations, the breast cancer market represents a great commercial opportunity for drug developers.\u00a0<abbr title=\"cyclin-dependent kinase 4\">CDK4<\/abbr>\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s\u00a0Kisqali, and Eli Lilly\u2019s Verzenio\/Verzenios\/Virginio) are creating new dynamics in the metastatic\u00a0<abbr title=\"hormone receptor\">HR<\/abbr>-positive\/<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative treatment practice. In\u00a0<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-positive breast cancer, emerging\u00a0<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-targeting drugs in development are forecast to enter the market, while current\u00a0<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-targeting agents will see their sales change as a result of competition, label expansions, <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854604173909885152723\">biosimilars<\/gwmw> entry, and new trials leading to changes in treatment guidelines. Furthermore, the approval of\u00a0<abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr>\u00a0inhibitors (AstraZeneca\u2019s Lynparza and Pfizer\u2019s Talzenna),\u00a0<abbr title=\"programmed cell death-1\">PD-1<\/abbr>-targeting\u00a0agents (Roche\/Genentech\/Chugai\u2019s\u00a0Tecentriq), and\u00a0<abbr title=\"phosphatidylinositol-4,5-bisphosphate 3-kinase\">PI3K<\/abbr>\u00a0inhibitors (Novartis\u2019s Piqray),\u00a0as well as anticipated entry of agents within these drug classes\u00a0will provide more diverse and much needed treatment options, especially for triple-negative breast cancer.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the size of the drug-treatable breast cancer population, and how <gwmw class=\"ginger-module-highlighter-mistake-type-2\" id=\"gwmw-15854604209704866640350\">will<\/gwmw> drug-treatment rates change over time?<\/li>\n<li>What is the expected market impact of recent drug approvals, such as the\u00a0<abbr title=\"cyclin-dependent kinase 4\">CDK4<\/abbr>\/6 inhibitors, immune checkpoint inhibitors,\u00a0<abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr>\u00a0 inhibitors, and\u00a0<abbr title=\"phosphatidylinositol-4,5-bisphosphate 3-kinase\">PI3K<\/abbr>\u00a0inhibitors in the various <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854604220627088056087\">subpopulations<\/gwmw> of breast cancer?<\/li>\n<li>What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?<\/li>\n<li>What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Contents Highlights<\/strong><\/p>\n<p>Geographies: United States,\u00a0<abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p>Primary Research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other\u00a0<abbr title=\"Decision Resources Group\">DRG<\/abbr>\u00a0research<\/p>\n<p>Epidemiology: Incidence of breast cancer by country, segmented by\u00a0<abbr title=\"hormone receptor\">HR<\/abbr>\u00a0and\u00a0<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>\u00a0status, staging, and line of therapy<\/p>\n<p>Forecast: 10-year, <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854604276310408681030\">annualized<\/gwmw>, drug-level sales and patient share of key breast cancer therapies through 2028, segmented by brands\/generics and market-relevant drug-treatable populations<\/p>\n<p>\u00a0Emerging Therapies: Phase III\/PR: 15\u00a0drugs; coverage of select Phase I and II products<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854604307378834726010\">comprehensive market intelligence<\/gwmw> with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390289","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390289\/revisions"}],"predecessor-version":[{"id":576548,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390289\/revisions\/576548"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}